from 19:55: ... the CDH17 ph 1 / 2 trial is designed that the ph2 is the registrational trial - that market approval, I think, could happen in 2026/27
Dr Bec is excited, her colleagues are excited, the hospitals are excited, the patients have some real hope, " Textbook response, Immune system activated, CAR-T cells still in blood after 28 days, unseen high activity but the ASX / big Pharma - not interested at all and Hopper more than happy to further devalue the company. Does not make sense, like 2 pilots pushing the plane in different directions.
The family office and its $4m donation already understand the value but the chair doesn't.
CHM Price at posting:
0.5¢ Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)